

Press Release

Zug, 9 February 2012

Successful Initial Public Offering of ChemoCentryx

ChemoCentryx (NASDAQ: CCXI), a portfolio company of HBM BioVentures, successfully completed its announced Initial Public Offering (IPO). The company raised a total of USD 45 million through the issue of 4.5 million shares at a price of USD 10.00 per share. The share of ChemoCentryx started trading on 8 February 2012 on the US stock exchange NASDAQ under the ticker CCXI and closed at a price of USD 11.00 (+10%) on the first trading day.

HBM BioVentures invested prior to the IPO a total of USD 13.7 million in ChemoCentryx and valued the investment at USD 18.5 million (USD 7 per share). Based on the closing share price on the first trading day the value of HBM BioVentures' investment increases to USD 29.0 million, which corresponds to a step-up of the net asset value per HBM BioVentures share (NAV) of CHF 1.06 (+1.9%).

ChemoCentryx has a broad development pipeline with several programs in clinical trials. Two drug candidates are licensed to GlaxoSmithKline (GSK): Traficet-EN, an investigational drug for the treatment of inflammatory bowel diseases such as Crohn's disease (currently in Phase III clinical trials) and CCX354, a phase II compound for the treatment of rheumatoid arthritis, a severe, chronic inflammatory disease. Besides, the company has a number of clinical programs that are not licensed to third parties, including CCX140, a drug candidate in phase II for the treatment of chronic kidney disease.

About ChemoCentryx

ChemoCentryx Inc., located in Mountain View (California), develops orally administered drugs for inflammatory diseases and other conditions, applying its proprietary platform for chemokine-based therapeutics. To find out more, visit the ChemoCentryx website at www.chemocentryx.com.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

HBM BioVentures

Profile of HBM BioVentures AG

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmbioventures.com
www.hbmbioventures.com